Roche Holding AG – LSE:0QQ6.L
Roche Holding AG stock price today
Roche Holding AG stock price monthly change
Roche Holding AG stock price quarterly change
Roche Holding AG stock price yearly change
Roche Holding AG key metrics
Market Cap | 202.86B |
Enterprise value | 235.79B |
P/E | 19.08 |
EV/Sales | 3.95 |
EV/EBITDA | 13.39 |
Price/Sales | 3.42 |
Price/Book | 7.00 |
PEG ratio | 35.80 |
EPS | 29.81 |
Revenue | 123.60B |
EBITDA | 43.57B |
Income | 23.91B |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 17.79% |
Oper. margin | 29.72% |
Gross margin | 73.61% |
EBIT margin | 29.72% |
EBITDA margin | 35.26% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeRoche Holding AG stock price history
Roche Holding AG stock forecast
Roche Holding AG financial statements
| Jun 2022 | 33.9B | 8.53B | 25.16% |
|---|---|---|---|
| Dec 2022 | 30.98B | 3.89B | 12.56% |
| Jun 2023 | 29.77B | 7.13B | 23.97% |
| Dec 2023 | 28.93B | 4.36B | 15.07% |
| 2025 | 64.64B | 15.73B | 24.33% |
|---|---|---|---|
| 2026 | 67.51B | 16.86B | 24.98% |
| 2027 | 70.15B | 17.90B | 25.52% |
| 2028 | 72.59B | 19.05B | 26.24% |
Analysts Price target
Financials & Ratios estimates
| Payout ratio | 72.29% |
|---|
| 2019 | 2.77% |
|---|---|
| 2020 | 2.91% |
| 2021 | 2.41% |
| 2022 | 3.2% |
| 2023 | 3.89% |
| Sep 2022 | 88151000000 | 56.13B | 63.68% |
|---|---|---|---|
| Dec 2022 | 88151000000 | 56.13B | 63.68% |
| Jun 2023 | 84370000000 | 54.02B | 64.03% |
| Dec 2023 | 90468000000 | 57.20B | 63.23% |
| Jun 2022 | 9.17B | 1.81B | -13.31B |
|---|---|---|---|
| Dec 2022 | 8.60B | -5.03B | -2.63B |
| Jun 2023 | 7.58B | -539M | -7.92B |
| Dec 2023 | 7.90B | -10.27B | 4.45B |
Roche Holding AG alternative data
| Aug 2023 | 103,613 |
|---|---|
| Sep 2023 | 103,613 |
| Oct 2023 | 103,613 |
| Nov 2023 | 103,613 |
| Dec 2023 | 103,613 |
| Jan 2024 | 103,613 |
| Feb 2024 | 103,613 |
| Mar 2024 | 103,605 |
| Apr 2024 | 103,605 |
| May 2024 | 103,605 |
| Jun 2024 | 103,605 |
| Jul 2024 | 103,605 |
Roche Holding AG other data
-
What's the price of Roche Holding AG stock today?
One share of Roche Holding AG stock can currently be purchased for approximately $290.8.
-
When is Roche Holding AG's next earnings date?
Unfortunately, Roche Holding AG's (0QQ6.L) next earnings date is currently unknown.
-
Does Roche Holding AG pay dividends?
Yes, Roche Holding AG pays dividends and its trailing 12-month yield is 3.79% with 72% payout ratio. The last Roche Holding AG stock dividend of undefined was paid on 3 Sep 2025.
-
How much money does Roche Holding AG make?
Roche Holding AG has a market capitalization of 202.86B and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 4.49% to 60.44B US dollars.
-
What is Roche Holding AG's stock symbol?
Roche Holding AG is traded on the LSE under the ticker symbol "0QQ6.L".
-
What is Roche Holding AG's primary industry?
Company operates in the Healthcare sector and Drug Manufacturers - General industry.
-
How do i buy shares of Roche Holding AG?
Shares of Roche Holding AG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Roche Holding AG have?
As Jul 2024, Roche Holding AG employs 103,605 workers.
-
When Roche Holding AG went public?
Roche Holding AG is publicly traded company for more then 11 years since IPO on 7 Mar 2014.
-
What is Roche Holding AG's official website?
The official website for Roche Holding AG is roche.com.
-
How can i contact Roche Holding AG?
Roche Holding AG can be reached via phone at +41 61 688 11 11.
Roche Holding AG company profile:
Roche Holding AG
roche.comLSE
103,605
Drug Manufacturers - General
Healthcare
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, Austria, Netherlands, the United Kingdom, France, Belgium, and internationally. The company offers pharmaceutical products for treating oncology, neuroscience, infectious, immunology, cardiovascular and metabolism, ophthalmology, and respiratory, as well as anemia, cancer, dermatology, hemophilia, inflammatory and autoimmune, neurological, and transplantation. It also offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases. In addition, the company supplies diagnostic instruments and reagents. It has a research collaboration agreement with Synlogic, Inc. for the discovery of a novel synthetic biotic for the treatment of inflammatory bowel disease (IBD). The company was founded in 1896 and is headquartered in Basel, Switzerland.
Basel, 4070
:
ISIN: CH0012032113
:
